FULL TEST BANK
LEHNE'S PHARMACOLOGY FOR NURSING CARE,
11TH EDITION
BY BURCHUM, ROSENTHAL; || ALL CHAPTERS 1-112
,TEST BANK - LEHNE'S PHARMACOLOGY FOR
NURSING CARE, 12TH EDITION ( JACQUELINE
BURCHUM, LAURA ROSENTHAL; 2024) LATEST
EDITION || ALL CHAPTERS 1-112
,TABLE OF CONTENTS
CHAPTER 01: ORIENTATION TO PHARMACOLOGY ........................................................................................ 6
CHAPTER 02: APPLICATION OF PHARMACOLOGY IN NURSING PRACTICE .................................................... 8
CHAPTER 03: DRUG REGULATION, DEVELOPMENT, NAMES, AND INFORMATION ..................................... 15
CHAPTER 04: PHARMACOKINETICS ............................................................................................................. 18
CHAPTER 05: PHARMACODYNAMICS .......................................................................................................... 25
CHAPTER 06: DRUG INTERACTIONS ............................................................................................................ 30
CHAPTER 07: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ...................................................... 36
CHAPTER 08: INDIVIDUAL VARIATION TO DRUG RESPONSES ..................................................................... 43
CHAPTER 09: GENETIC AND GENOMIC CONSIDERATIONS .......................................................................... 49
CHAPTER 10: INTRODUCTION TO IMMUNOMODULATORS ........................................................................ 54
CHAPTER 11: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING .............................................. 58
CHAPTER 12: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................... 63
CHAPTER 13: DRUG THERAPY IN OLDER ADULTS ........................................................................................ 69
CHAPTER 14: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .................................................................... 76
CHAPTER 15: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM........................................................... 79
CHAPTER 16: MUSCARINIC AGONISTS ........................................................................................................ 84
CHAPTER 17: MUSCARINIC ANTAGONISTS .................................................................................................. 88
CHAPTER 18: CHOLINESTERASE INHIBITORS AND THEIR USE IN MYASTHENIA GRAVIS ............................. 92
CHAPTER 19: DRUGS THAT BLOCK NICOTINIC CHOLINERGIC TRANSMISSION ............................................ 97
CHAPTER 20: ADRENERGIC AGONISTS ...................................................................................................... 103
CHAPTER 21: ADRENERGIC ANTAGONISTS................................................................................................ 108
CHAPTER 22: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................... 116
CHAPTER 23: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY ................................... 122
CHAPTER 24: DRUGS FOR PARKINSON DISEASE ........................................................................................ 126
CHAPTER 25: DRUGS FOR ALZHEIMER DISEASE ........................................................................................ 134
CHAPTER 26: DRUGS FOR MULTIPLE SCLEROSIS ....................................................................................... 139
CHAPTER 27: DRUGS FOR SEIZURE DISORDERS ........................................................................................ 146
CHAPTER 28: DRUGS FOR MUSCLE SPASM AND SPASTICITY .................................................................... 156
, CHAPTER 29: LOCAL ANESTHETICS ............................................................................................................ 161
CHAPTER 30: GENERAL ANESTHETICS ....................................................................................................... 167
CHAPTER 31: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS
.................................................................................................................................................................. 174
CHAPTER 32: PAIN MANAGEMENT IN PATIENTS WITH CANCER ............................................................... 182
CHAPTER 33: DRUGS FOR HEADACHE ....................................................................................................... 191
CHAPTER 34: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ............................................ 198
CHAPTER 35: ANTIDEPRESSANTS .............................................................................................................. 205
CHAPTER 36: DRUGS FOR BIPOLAR DISORDER.......................................................................................... 215
CHAPTER 37: SEDATIVE-HYPNOTIC DRUGS ............................................................................................... 221
CHAPTER 38: MANAGEMENT OF ANXIETY DISORDERS ............................................................................. 229
CHAPTER 40: SUBSTANCE USE DISORDERS I: BASIC CONSIDERATIONS .................................................... 240
CHAPTER 41: SUBSTANCE USE DISORDERS II: ALCOHOL ........................................................................... 245
CHAPTER 42: SUBSTANCE USE DISORDERS III: NICOTINE.......................................................................... 254
CHAPTER 43: SUBSTANCE USE DISORDERS IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE
.................................................................................................................................................................. 259
CHAPTER 44: DIURETICS ............................................................................................................................ 268
CHAPTER 45: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ........................... 274
CHAPTER 46: REVIEW OF HEMODYNAMICS .............................................................................................. 281
CHAPTER 47: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ............................. 284
CHAPTER 48: CALCIUM CHANNEL BLOCKERS ............................................................................................ 290
CHAPTER 49: VASODILATORS .................................................................................................................... 294
CHAPTER 50: DRUGS FOR HYPERTENSION ................................................................................................ 299
CHAPTER 51: DRUGS FOR HEART FAILURE ................................................................................................ 309
CHAPTER 52: ANTIDYSRHYTHMIC DRUGS ................................................................................................. 319
CHAPTER 53: DRUGS THAT HELP NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................... 329
CHAPTER 54: DRUGS FOR ANGINA PECTORIS ........................................................................................... 339
CHAPTER 55: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ....................................... 347
CHAPTER 56: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ........................................... 356
CHAPTER 57: DRUGS FOR HEMOPHILIA .................................................................................................... 363
LEHNE'S PHARMACOLOGY FOR NURSING CARE,
11TH EDITION
BY BURCHUM, ROSENTHAL; || ALL CHAPTERS 1-112
,TEST BANK - LEHNE'S PHARMACOLOGY FOR
NURSING CARE, 12TH EDITION ( JACQUELINE
BURCHUM, LAURA ROSENTHAL; 2024) LATEST
EDITION || ALL CHAPTERS 1-112
,TABLE OF CONTENTS
CHAPTER 01: ORIENTATION TO PHARMACOLOGY ........................................................................................ 6
CHAPTER 02: APPLICATION OF PHARMACOLOGY IN NURSING PRACTICE .................................................... 8
CHAPTER 03: DRUG REGULATION, DEVELOPMENT, NAMES, AND INFORMATION ..................................... 15
CHAPTER 04: PHARMACOKINETICS ............................................................................................................. 18
CHAPTER 05: PHARMACODYNAMICS .......................................................................................................... 25
CHAPTER 06: DRUG INTERACTIONS ............................................................................................................ 30
CHAPTER 07: ADVERSE DRUG REACTIONS AND MEDICATION ERRORS ...................................................... 36
CHAPTER 08: INDIVIDUAL VARIATION TO DRUG RESPONSES ..................................................................... 43
CHAPTER 09: GENETIC AND GENOMIC CONSIDERATIONS .......................................................................... 49
CHAPTER 10: INTRODUCTION TO IMMUNOMODULATORS ........................................................................ 54
CHAPTER 11: DRUG THERAPY DURING PREGNANCY AND BREAST-FEEDING .............................................. 58
CHAPTER 12: DRUG THERAPY IN PEDIATRIC PATIENTS ............................................................................... 63
CHAPTER 13: DRUG THERAPY IN OLDER ADULTS ........................................................................................ 69
CHAPTER 14: BASIC PRINCIPLES OF NEUROPHARMACOLOGY .................................................................... 76
CHAPTER 15: PHYSIOLOGY OF THE PERIPHERAL NERVOUS SYSTEM........................................................... 79
CHAPTER 16: MUSCARINIC AGONISTS ........................................................................................................ 84
CHAPTER 17: MUSCARINIC ANTAGONISTS .................................................................................................. 88
CHAPTER 18: CHOLINESTERASE INHIBITORS AND THEIR USE IN MYASTHENIA GRAVIS ............................. 92
CHAPTER 19: DRUGS THAT BLOCK NICOTINIC CHOLINERGIC TRANSMISSION ............................................ 97
CHAPTER 20: ADRENERGIC AGONISTS ...................................................................................................... 103
CHAPTER 21: ADRENERGIC ANTAGONISTS................................................................................................ 108
CHAPTER 22: INDIRECT-ACTING ANTIADRENERGIC AGENTS .................................................................... 116
CHAPTER 23: INTRODUCTION TO CENTRAL NERVOUS SYSTEM PHARMACOLOGY ................................... 122
CHAPTER 24: DRUGS FOR PARKINSON DISEASE ........................................................................................ 126
CHAPTER 25: DRUGS FOR ALZHEIMER DISEASE ........................................................................................ 134
CHAPTER 26: DRUGS FOR MULTIPLE SCLEROSIS ....................................................................................... 139
CHAPTER 27: DRUGS FOR SEIZURE DISORDERS ........................................................................................ 146
CHAPTER 28: DRUGS FOR MUSCLE SPASM AND SPASTICITY .................................................................... 156
, CHAPTER 29: LOCAL ANESTHETICS ............................................................................................................ 161
CHAPTER 30: GENERAL ANESTHETICS ....................................................................................................... 167
CHAPTER 31: OPIOID ANALGESICS, OPIOID ANTAGONISTS, AND NONOPIOID CENTRALLY ACTING ANALGESICS
.................................................................................................................................................................. 174
CHAPTER 32: PAIN MANAGEMENT IN PATIENTS WITH CANCER ............................................................... 182
CHAPTER 33: DRUGS FOR HEADACHE ....................................................................................................... 191
CHAPTER 34: ANTIPSYCHOTIC AGENTS AND THEIR USE IN SCHIZOPHRENIA ............................................ 198
CHAPTER 35: ANTIDEPRESSANTS .............................................................................................................. 205
CHAPTER 36: DRUGS FOR BIPOLAR DISORDER.......................................................................................... 215
CHAPTER 37: SEDATIVE-HYPNOTIC DRUGS ............................................................................................... 221
CHAPTER 38: MANAGEMENT OF ANXIETY DISORDERS ............................................................................. 229
CHAPTER 40: SUBSTANCE USE DISORDERS I: BASIC CONSIDERATIONS .................................................... 240
CHAPTER 41: SUBSTANCE USE DISORDERS II: ALCOHOL ........................................................................... 245
CHAPTER 42: SUBSTANCE USE DISORDERS III: NICOTINE.......................................................................... 254
CHAPTER 43: SUBSTANCE USE DISORDERS IV: MAJOR DRUGS OF ABUSE OTHER THAN ALCOHOL AND NICOTINE
.................................................................................................................................................................. 259
CHAPTER 44: DIURETICS ............................................................................................................................ 268
CHAPTER 45: AGENTS AFFECTING THE VOLUME AND ION CONTENT OF BODY FLUIDS ........................... 274
CHAPTER 46: REVIEW OF HEMODYNAMICS .............................................................................................. 281
CHAPTER 47: DRUGS ACTING ON THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM ............................. 284
CHAPTER 48: CALCIUM CHANNEL BLOCKERS ............................................................................................ 290
CHAPTER 49: VASODILATORS .................................................................................................................... 294
CHAPTER 50: DRUGS FOR HYPERTENSION ................................................................................................ 299
CHAPTER 51: DRUGS FOR HEART FAILURE ................................................................................................ 309
CHAPTER 52: ANTIDYSRHYTHMIC DRUGS ................................................................................................. 319
CHAPTER 53: DRUGS THAT HELP NORMALIZE CHOLESTEROL AND TRIGLYCERIDE LEVELS ....................... 329
CHAPTER 54: DRUGS FOR ANGINA PECTORIS ........................................................................................... 339
CHAPTER 55: ANTICOAGULANT, ANTIPLATELET, AND THROMBOLYTIC DRUGS ....................................... 347
CHAPTER 56: MANAGEMENT OF ST-ELEVATION MYOCARDIAL INFARCTION ........................................... 356
CHAPTER 57: DRUGS FOR HEMOPHILIA .................................................................................................... 363
